CLINICAL STUDIES
Cardiac metaiodobenzylguanidine uptake in patients with moderate chronic heart failure: relationship with peak oxygen uptake and prognosis
Alain Cohen-Solal, MD, PhD, FESC*,
Yves Esanu, MD*,
Damien Logeart, MD*,
Fabienne Pessione, MD*,
Claude Dubois, MD ,
Gilles Dreyfus, MD ,
René Gourgon, MD* and
Pascal Merlet, MD, PhD
* Hôpitaux Beaujon, Clichy, France
Foch, Suresnes, France
Centre Hospitalier Frederic Joliot, Orsay, France
Manuscript received May 19, 1998;
revised manuscript received September 28, 1998,
accepted November 5, 1998.
Reprint requests and correspondence: Pr. Alain Cohen-Solal, Service de Cardiologie, Hôpital Beaujon, 100 Boulevard du General Leclerc, 92110 Clichy, France alain.cohen-solal{at}bjn.ap-hop-paris.fr
OBJECTIVES
This prospective study was undertaken to correlate early and late metaiodobenzylguanidine (MIBG) cardiac uptake with cardiac hemodynamics and exercise capacity in patients with heart failure and to compare their prognostic values with that of peak oxygen uptake (VO2).
BACKGROUND
The cardiac fixation of MIBG reflects presynaptic uptake and is reduced in heart failure. Whether it is related to exercise capacity and has better prognostic value than peak VO2 is unknown.
METHODS
Ninety-three patients with heart failure (ejection fraction <45%) were studied with planar MIBG imaging, cardiopulmonary exercise tests and hemodynamics (n = 44). Early (20 min) and late (4 h) MIBG acquisition, as well as their ratio (washout, WO) were determined. Prognostic value was assessed by survival curves (KaplanMeier method) and uni- and multivariate Cox analyses.
RESULTS
Late cardiac MIBG uptake was reduced (131 ± 20%, normal values 192 ± 42%) and correlated with ejection fraction (r = 0.49), cardiac index (r = 0.40) and pulmonary wedge pressure (r = 0.35). There was a significant correlation between peak VO2 and MIBG uptake (r = 0.41, p < 0.0001). With a mean follow-up of 10 ± 8 months, both late MIBG uptake (p = 0.04) and peak VO2 (p < 0.0001) were predictive of death or heart transplantation, but only peak VO2 emerged by multivariate analysis. Neither early MIBG uptake nor WO yielded significant insights beyond those provided by late MIBG uptake.
CONCLUSIONS
Metaiodobenzylguanidine uptake has prognostic value in patients with wide ranges of heart failure, but peak VO2 remains the most powerful prognostic index.
|
Abbreviations and Acronyms
| | CHF | = chronic heart failure | | EF | = ejection fraction | | H/M | = heart/mediastinum | | MIBG | = metaiodobenzylguanidine | | NYHA | = New York Heart Association | | ROC | = receiver operating characteristic | | VO2 | = oxygen uptake | | WO | = wash-out |
|
This article has been cited by other articles:

|
 |

|
 |
 
H. J. Verberne, L. M. Brewster, G. A. Somsen, and B. L.F. van Eck-Smit
Prognostic value of myocardial 123I-metaiodobenzylguanidine (MIBG) parameters in patients with heart failure: a systematic review
Eur. Heart J.,
May 1, 2008;
29(9):
1147 - 1159.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Kioka, T. Yamada, T. Mine, T. Morita, Y. Tsukamoto, S. Tamaki, M. Masuda, K. Okuda, M. Hori, and M. Fukunami
Prediction of sudden death in patients with mild-to-moderate chronic heart failure by using cardiac iodine-123 metaiodobenzylguanidine imaging
Heart,
October 1, 2007;
93(10):
1213 - 1218.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. A. Gould, G. Kong, V. Kalff, S. J. Duffy, A. J. Taylor, M. J. Kelly, and D. M. Kaye
Improvement in cardiac adrenergic function post biventricular pacing for heart failure
Europace,
September 1, 2007;
9(9):
751 - 756.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Cohen-Solal, F. Rouzet, A. Berdeaux, D. Le Guludec, E. Abergel, A. Syrota, and P. Merlet
Effects of Carvedilol on Myocardial Sympathetic Innervation in Patients with Chronic Heart Failure
J. Nucl. Med.,
November 1, 2005;
46(11):
1796 - 1803.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Sato, K. Maehara, H. Yaoita, H. Otani, A. Hirosaka, T. Saito, N. Onuki, N. Komatsu, T. Ishihata, and Y. Maruyama
Correlation Between Cardiac Norepinephrine Overflow During Exercise and Cardiac 123I-MIBG Uptake in Patients with Chronic Heart Failure
J. Nucl. Med.,
October 1, 2003;
44(10):
1618 - 1624.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Muxi, J. Magrina, F. Martin, M. Josa, D. Fuster, F. J. Setoain, F. Perez-Villa, J. Pavia, and X. Bosch
Technetium 99m-labeled tetrofosmin and iodine 123-labeled metaiodobenzylguanidine scintigraphy in the assessment of transmyocardial laser revascularization
J. Thorac. Cardiovasc. Surg.,
June 1, 2003;
125(6):
1493 - 1498.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Yamada, T. Shimonagata, M. Fukunami, K. Kumagai, H. Ogita, A. Hirata, M. Asai, N. Makino, H. Kioka, H. Kusuoka, et al.
Comparison of the prognostic value of cardiac iodine-123 metaiodobenzylguanidine imaging and heart rate variability in patients with chronic heart failure: A prospective study
J. Am. Coll. Cardiol.,
January 15, 2003;
41(2):
231 - 238.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Jourdain, F. Funck, Y. Fulla, A. Hagege, M. Bellorini, N. Guillard, J. Loiret, B. Thebault, and M. Desnos
Myocardial contractile reserve under low doses of dobutamine and improvement of left ventricular ejection fraction with treatment by carvedilol
Eur J Heart Fail,
June 1, 2002;
4(3):
269 - 276.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Cohen-Solal, J.Y. Tabet, D. Logeart, P. Bourgoin, M. Tokmakova, and M. Dahan
A non-invasively determined surrogate of cardiac power ('circulatory power') at peak exercise is a powerful prognostic factor in chronic heart failure
Eur. Heart J.,
May 2, 2002;
23(10):
806 - 814.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Merlet, L. Hittinger, J. L. Dubois-Rande, and A. Castaigne
Myocardial Adrenergic Dysinnervation in Dilated Cardiomyopathy: Cornerstone or Epiphenomenon?
J. Nucl. Med.,
April 1, 2002;
43(4):
536 - 539.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Shimizu, H. Ino, M. Yamaguchi, H. Terai, K. Hayashi, K. Nakajima, J. Taki, and H. Mabuchi
Heterogeneity of Cardiac Sympathetic Nerve Activity and Systolic Dysfunction in Patients with Hypertrophic Cardiomyopathy
J. Nucl. Med.,
January 1, 2002;
43(1):
15 - 20.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H Ogita, T Shimonagata, M Fukunami, K Kumagai, T Yamada, Y Asano, A Hirata, M Asai, H Kusuoka, M Hori, et al.
Prognostic significance of cardiac 123I metaiodobenzylguanidine imaging for mortality and morbidity in patients with chronic heart failure: a prospective study
Heart,
December 1, 2001;
86(6):
656 - 660.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Wakabayashi, T. Nakata, A. Hashimoto, S. Yuda, K. Tsuchihashi, M. I. Travin, and K. Shimamoto
Assessment of Underlying Etiology and Cardiac Sympathetic Innervation to Identify Patients at High Risk of Cardiac Death
J. Nucl. Med.,
December 1, 2001;
42(12):
1757 - 1767.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. A.R. de Milliano, B. L.F. van Eck-Smit, P. A. van Zwieten, A. C. de Groot, J. G.P. Tijssen, and K. I. Lie
Relationship between cardiac metaiodobenzylguanidine uptake and hemodynamic, functional and neurohormonal parameters in patients with heart failure
Eur J Heart Fail,
December 1, 2001;
3(6):
693 - 697.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P Acar, P Merlet, L Iserin, D Bonnet, D Sidi, A Syrota, and J Kachaner
Impaired cardiac adrenergic innervation assessed by MIBG imaging as a predictor of treatment response in childhood dilated cardiomyopathy
Heart,
June 1, 2001;
85(6):
692 - 696.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
J.-Y. Tabet, D. Logeart, C. Geyer, C. Guiti, P.V. Ennezat, M. Dahan, and A. Cohen-Solal
Comparison of the prognostic value of left ventricular filling and peak oxygen uptake in patients with systolic heart failure
Eur. Heart J.,
November 2, 2000;
21(22):
1864 - 1871.
[Abstract]
[PDF]
|
 |
|
|